Craig Hallum Increases Henry Schein (HSIC) Price Target to $96.00
Henry Schein (NASDAQ:HSIC) had its price target raised by analysts at Craig Hallum from $83.00 to $96.00 in a report released on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price target points to a potential upside of 20.89% from the company’s previous close.
A number of other research analysts also recently issued reports on the company. ValuEngine downgraded Henry Schein from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. Goldman Sachs Group downgraded Henry Schein from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 24th. BidaskClub upgraded Henry Schein from a “sell” rating to a “hold” rating in a research note on Saturday, April 14th. Northcoast Research set a $102.00 price target on Henry Schein and gave the stock a “buy” rating in a research note on Tuesday, April 24th. Finally, Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research note on Tuesday, April 24th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $84.11.
Shares of Henry Schein traded down $0.39, reaching $79.41, during mid-day trading on Tuesday, according to Marketbeat Ratings. The company’s stock had a trading volume of 7,118 shares, compared to its average volume of 1,124,315. Henry Schein has a 12-month low of $62.56 and a 12-month high of $89.75. The company has a market cap of $12.36 billion, a P/E ratio of 21.96, a PEG ratio of 1.91 and a beta of 1.00. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.74 and a current ratio of 1.44.
In other Henry Schein news, Director Paul Brons sold 4,822 shares of Henry Schein stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $72.93, for a total value of $351,668.46. Following the transaction, the director now directly owns 20,889 shares in the company, valued at approximately $1,523,434.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Mark E. Mlotek sold 10,359 shares of Henry Schein stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $72.73, for a total value of $753,410.07. Following the completion of the transaction, the executive vice president now owns 79,506 shares in the company, valued at $5,782,471.38. The disclosure for this sale can be found here. Company insiders own 1.15% of the company’s stock.
Several hedge funds have recently made changes to their positions in the business. Canada Pension Plan Investment Board grew its stake in shares of Henry Schein by 2,487.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 127,844 shares of the company’s stock valued at $9,287,000 after purchasing an additional 122,903 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Henry Schein by 57.1% in the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock valued at $160,000 after purchasing an additional 800 shares during the last quarter. Bellevue Group AG grew its stake in shares of Henry Schein by 19.5% in the 2nd quarter. Bellevue Group AG now owns 51,368 shares of the company’s stock valued at $3,731,000 after purchasing an additional 8,368 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of Henry Schein by 19.2% in the 2nd quarter. Toronto Dominion Bank now owns 98,984 shares of the company’s stock valued at $7,187,000 after purchasing an additional 15,912 shares during the last quarter. Finally, Quest Investment Management LLC purchased a new position in shares of Henry Schein in the 2nd quarter valued at approximately $214,000.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Article: Trading Strategy Methods and Types
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.